Stay updated with breaking news from Valuating. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The trial did not meet its primary endpoint of overall survival (OS) The safety profile of the combination of cabozantinib and atezolizumab was consistent with the known safety profiles for
Salt Lake City, Utah--(Newsfile Corp. - November 17, 2022) - Kiora Pharmaceuticals, Inc. (NASDAQ: KPRX) ("Kiora" or the "Company") announced today the dosing of the first patient in a first-in-human open-label
KELOWNA, BC / ACCESSWIRE / November 8, 2022 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the "Company" or "Lexaria"), a global innovator in drug delivery platforms announces that study program
Based on promising progression-free survival (PFS) interim analysis, trial to continue and an optimized number of patients to be randomized in the trial Management to host webcast presentation of
~ Announces Timing of Corporate Update Call ~SAN DIEGO, CA / ACCESSWIRE / October 31, 2022 / Ensysce Biosciences Inc. ("Ensysce" or the "Company") (NASDAQ:ENSC)(OTC PINK:ENSCW), a clinical-stage biotech